DE69131992T2 - Papillomavirusuntereinheit-impfstoff - Google Patents

Papillomavirusuntereinheit-impfstoff

Info

Publication number
DE69131992T2
DE69131992T2 DE69131992T DE69131992T DE69131992T2 DE 69131992 T2 DE69131992 T2 DE 69131992T2 DE 69131992 T DE69131992 T DE 69131992T DE 69131992 T DE69131992 T DE 69131992T DE 69131992 T2 DE69131992 T2 DE 69131992T2
Authority
DE
Germany
Prior art keywords
papillomavirus
sequence
vaccine
drahyni
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69131992T
Other languages
English (en)
Other versions
DE69131992D1 (de
Inventor
Robert Tindle
Germain Fermando
Ian Frazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
CSL Ltd
Original Assignee
University of Queensland UQ
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, CSL Ltd filed Critical University of Queensland UQ
Application granted granted Critical
Publication of DE69131992D1 publication Critical patent/DE69131992D1/de
Publication of DE69131992T2 publication Critical patent/DE69131992T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69131992T 1990-12-12 1991-12-12 Papillomavirusuntereinheit-impfstoff Expired - Lifetime DE69131992T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPK387690 1990-12-12
PCT/AU1991/000575 WO1992010513A1 (en) 1990-12-12 1991-12-12 Subunit papillomavirus vaccine and peptides for use therein

Publications (2)

Publication Number Publication Date
DE69131992D1 DE69131992D1 (de) 2000-03-23
DE69131992T2 true DE69131992T2 (de) 2000-06-29

Family

ID=3775135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131992T Expired - Lifetime DE69131992T2 (de) 1990-12-12 1991-12-12 Papillomavirusuntereinheit-impfstoff

Country Status (7)

Country Link
EP (1) EP0561885B1 (de)
JP (1) JPH06503559A (de)
KR (1) KR100252371B1 (de)
AT (1) ATE189818T1 (de)
CA (1) CA2097916C (de)
DE (1) DE69131992T2 (de)
WO (1) WO1992010513A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP1288292A1 (de) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Lange Peptiden die 22-40 Aminosäuren enthalten und die eine immunspezifische Immunantwort induzieren
WO2002100889A1 (en) * 2001-06-08 2002-12-19 Kirin Beer Kabushiki Kaisha Novel epitope of human papilloma virus e7 antigen and cd4-positive t cells activated by the epitope
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641081A1 (de) * 1988-12-23 1990-06-29 Medgenix Group
PT97073A (pt) * 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
ATE234860T1 (de) * 1991-07-13 2003-04-15 Dade Behring Marburg Gmbh Verwendung von hpv-16 e6 und e7-gen gewonnen peptiden für den diagnostischen zweck

Also Published As

Publication number Publication date
EP0561885A4 (en) 1994-09-21
WO1992010513A1 (en) 1992-06-25
CA2097916A1 (en) 1992-06-13
DE69131992D1 (de) 2000-03-23
KR100252371B1 (ko) 2000-05-01
EP0561885A1 (de) 1993-09-29
EP0561885B1 (de) 2000-02-16
JPH06503559A (ja) 1994-04-21
ATE189818T1 (de) 2000-03-15
CA2097916C (en) 2001-08-21

Similar Documents

Publication Publication Date Title
DE69131992T2 (de) Papillomavirusuntereinheit-impfstoff
MX2022010118A (es) Peptidos y proteinas de dise?o para la deteccion, la prevencion y el tratamiento de la enfermedad por coronavirus de 2019 (covid-19).
DK0593754T3 (da) Peptider fra humant papillomavirus til anvendelse i præparater til induktion af humant T-celle respons
BR9814487A (pt) "vacina"
FR07C0073I2 (fr) Vaccin contre le papillomavirus
CA2074153A1 (en) Seroreactive regions on hpv 16 proteins e1 and e2
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
MA24638A1 (fr) Vaccin
DE69206631D1 (de) Impfstoff gegen das Fortpflanzungs- und Atmungssyndrom bei Schweinen (PRRS) und Diagnose.
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
HUP0301308A2 (hu) Emberi Papillomavírus-fertőzés gyógykezelése
DE59608274D1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
HUP0303942A2 (hu) Új vakcinakészítmények
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
ATE193974T1 (de) Chlamydia impfstoffen
HUP0202770A2 (hu) Humán papillómavírus oltóanyag
DK0762895T3 (da) Syntetisk vaccine til beskyttelse mod infektion med human immundefektvirus
NZ295056A (en) Hepatitis virus e strain, recombinant proteins thereof, use in diagnostic methods and vaccines
AUPN712795A0 (en) Recombinant vaccines
WO1999024466A3 (en) Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
EP0808846A3 (de) Peptide, die mit Antikörpern reagieren, die den Fortschritt der HIV-Erkrankung markieren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition